Dissolution and bracketing [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-03-21 17:39 (213 d 12:46 ago) – Posting: # 21292
Views: 1,688

(edited by wienui on 2020-03-21 18:36)

Hi Susanh,

» Can bracketing be used for additional strengths were the dissolution is not similar? Could BE-studies been done on the highest and lowest strength and not on middle strengths in this case?

Bracketing approach (when deviation from biowaiver criteria exist ) for additional strength Biowaivers is allowed according to both EMA and FDA but they differ in the principle for selecting the strengthes for which the 2 BE studies should be performed.

For EMA: Strengths selected must represent the extreme of deviation(s) from biowaiver conditions:-
Proportionality of strengths
Similarity of dissolution
Linearity of pharmacokinetics (under fasted and/or fed administration)

i.e in your case the two strength which differ in Similarity of dissolution and ( proportionality or PK linearity)

For FDA : The 2 BE-studies must be done on the highest and lowest strengthes.

Best regards,

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,170 posts in 4,411 threads, 1,474 registered users;
online 7 (0 registered, 7 guests [including 2 identified bots]).
Forum time: Wednesday 07:25 CEST (Europe/Vienna)

But it is in matters beyond the limits of mere rule
that the skill of the analyst is evinced.
He makes in silence a host of observations and inferences…    Edgar Allan Poe

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5